One of the most promising small-molecule caspase-3-targeting ABPs, [18F]ICMT-11, was extensively evaluated preclinically, where it showed the ability to detect tumor response to different anticancer therapies in several tumor models. This evidence concerns the gene CASP3 and neoplasm.